The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/IIA safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.
Michael Morse
No relevant relationships to disclose
Luis A. Diaz
No relevant relationships to disclose
Nilofer Saba Azad
No relevant relationships to disclose
Dan Laheru
No relevant relationships to disclose
Sherri Haley
No relevant relationships to disclose
Leanne Sophia Sleer
Employment or Leadership Position - Neogenix Oncology
Stock Ownership - Neogenix Oncology
Philip M. Arlen
Employment or Leadership Position - Neogenix Oncology
Stock Ownership - Neogenix Oncology